AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37344801 — intervention group
Group type: COMPARATOR
Intervention: Fluid challenges (36 positive and 68 negative)
Number of subjects: 69
Study 37344825 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype 1 (n=105, 45.3%)
Number of subjects: 232
Study 37344825 — intervention group
Group type: COMPARATOR
Intervention: Subtype 2 (n=127, 54.7%)
Number of subjects: 232
Study 37344825 — intervention group
Group type: COMPARATOR
Intervention: 52-gene signature risk groups
Number of subjects: 232
Study 37344887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold nanoparticles and gold nanorods
Number of subjects: 0
Study 37344895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b at a dosing regimen of 250-350-500 μg
Number of subjects: 49
Study 37344895 — intervention group
Group type: COMPARATOR
Intervention: Approved dosing schema of ropeginterferon alfa-2b (starting dose of 100 µg)
Number of subjects: 49
Study 37344997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.05 mg/kg
Number of subjects: 22
Study 37344997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 37345084 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IMRT of 45-50 Gy with a simultaneous integrated boost of 50-56 Gy, followed by surgery and IORT.
Number of subjects: 37
Study 37345084 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IMRT of > 50 Gy plus IORT boost.
Number of subjects: 37
Study 37345084 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group).
Number of subjects: 37
Study 37345196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAK1/JAK2 inhibitor)
Number of subjects: 1120
Study 37345256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous culture-expanded adipose-derived mesenchymal stem cells (ADMSCs)
Number of subjects: 261
Study 37345256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 37345518 — intervention group
Group type: EXPERIMENTAL
Intervention: HT with pretransplant MCS
Number of subjects: 227
Study 37345518 — intervention group
Group type: EXPERIMENTAL
Intervention: HT without pretransplant MCS
Number of subjects: 227
Study 37345518 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term MCS
Number of subjects: 227
Study 37345544 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy for RAS with moderate depressive symptoms
Number of subjects: 0
Study 37345627 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0
Study 37345645 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 1000
Study 37345645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 37345661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat restriction
Number of subjects: 17
Study 37345661 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric baseline diet
Number of subjects: 17
Study 37345754 — intervention group
Group type: COMPARATOR
Intervention: Baseline model without WMH
Number of subjects: 727
Study 37345754 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with WMH included
Number of subjects: 727
Study 37345754 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident stroke or cognitive decline
Number of subjects: 727
Study 37345805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic-mediated hyperemia with intracoronary adenosine or nitroprusside (n=30)
Number of subjects: 67
Study 37345805 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated hyperemia (n=37)
Number of subjects: 67
Study 37345815 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet participation
Number of subjects: 0
Study 37345815 — intervention group
Group type: COMPARATOR
Intervention: Noninternet participation
Number of subjects: 0
Study 37345813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve edge-to-edge repair
Number of subjects: 2534
Study 37345834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 11551
Study 37345834 — intervention group
Group type: COMPARATOR
Intervention: Standard deviation of SBP variability
Number of subjects: 11551
Study 37345834 — intervention group
Group type: COMPARATOR
Intervention: SBP variability
Number of subjects: 11551
Study 37345876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide 2 mg per day for 144 weeks
Number of subjects: 150
Study 37345876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide 10 mg per day for 144 weeks
Number of subjects: 150
Study 37345876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 48 weeks followed by bulevirtide 10 mg per day for 96 weeks)
Number of subjects: 150
Study 37345996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention (acute HIV testing, contract partner notification (cPN), and social contact referral)
Number of subjects: 0
Study 37345996 — intervention group
Group type: COMPARATOR
Intervention: Contract partner notification (cPN) alone
Number of subjects: 0
Study 37345996 — intervention group
Group type: COMPARATOR
Intervention: Passive partner notification (pPN)
Number of subjects: 0
Study 37345996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 0
Study 37346892 — intervention group
Group type: EXPERIMENTAL
Intervention: Crawling on a mini-skateboard (Crawli)
Number of subjects: 44
Study 37346892 — intervention group
Group type: COMPARATOR
Intervention: Prone positioning control (Mattress)
Number of subjects: 44
Study 37346892 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 44
Study 37346899 — intervention group
Group type: EXPERIMENTAL
Intervention: Gothenburg Treatment for Gaming Disorder (GOT-TO-GO) manual; a 15-week cognitive behavioral therapy treatment for GD
Number of subjects: 0
Study 37347015 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoconductive scaffold augmentation at the femoral tunnel aperture
Number of subjects: 56
Study 37347015 — intervention group
Group type: COMPARATOR
Intervention: Control group with femoral fixation using cortical suspension fixation and secondary press-fit fixation
Number of subjects: 56
Study 37347015 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoconductive scaffold intervention
Number of subjects: 56
Study 37347294 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level fusion surgery
Number of subjects: 38
Study 37347370 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IFN-α2b 2.5 MIU twice daily for 10 days (n = 6)
Number of subjects: 12
Study 37347370 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IFN-α2b 5.0 MIU twice daily for 10 days (n = 6)
Number of subjects: 12
Study 37347370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 12
Study 37347370 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IFN-α2b (both doses)
Number of subjects: 12
Study 37347393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Number of subjects: 142
Study 37347393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 37347517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia CHAT (D-CHAT)
Number of subjects: 0
Study 37347518 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia web-based video consent
Number of subjects: 79
Study 37347518 — intervention group
Group type: COMPARATOR
Intervention: Conventional written consent document
Number of subjects: 79
Study 37347521 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone ownership and usage patterns among enrolled women
Number of subjects: 639
Study 37347538 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled morning assessments
Number of subjects: 257
Study 37347538 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assessments
Number of subjects: 257
Study 37347538 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 257
Study 37347538 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time employed participants
Number of subjects: 257
Study 37347538 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who dropped out of the study
Number of subjects: 257
Study 37347538 — intervention group
Group type: EXPERIMENTAL
Intervention: White participants
Number of subjects: 257
Study 37347553 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Cryptosporidium antigens (Cp23, Cp17, Gp900, CpSMP1, CpMuc8, CpCorA, CpCCDC1)
Number of subjects: 0
Study 37347553 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody responses
Number of subjects: 0
Study 37347686 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI Natural History and Biospecimens Acquisitions Study for Children and Adults with Rare Solid Tumors protocol (NCT03739827)
Number of subjects: 12
Study 37347686 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary expert clinic
Number of subjects: 12
Study 37347686 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review of pediatric PDC and DC
Number of subjects: 12
Study 37347686 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approaches
Number of subjects: 12
Study 37347913 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telehealth cognitive behavioral treatment
Number of subjects: 268
Study 37347913 — intervention group
Group type: COMPARATOR
Intervention: In-person cognitive behavioral treatment
Number of subjects: 268
Study 37347964 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min nap
Number of subjects: 26
Study 37347964 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hr nap
Number of subjects: 26
Study 37347964 — intervention group
Group type: COMPARATOR
Intervention: No-nap condition
Number of subjects: 26
Study 37347968 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min nap opportunity
Number of subjects: 28
Study 37347968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hr nap opportunity
Number of subjects: 28
Study 37347968 — intervention group
Group type: COMPARATOR
Intervention: No-nap
Number of subjects: 28
Study 37347984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal manipulation (high-velocity, low-amplitude technique)
Number of subjects: 44
Study 37347984 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (manual contact under the head)
Number of subjects: 44
Study 37348019 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Number of subjects: 290
Study 37348019 — intervention group
Group type: COMPARATOR
Intervention: Standard endocrine treatment of physician's choice (TPC)
Number of subjects: 290
Study 37348035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 37348035 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 37348093 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mm Hg insufflation pressure (experimental group)
Number of subjects: 80
Study 37348093 — intervention group
Group type: COMPARATOR
Intervention: 15 mm Hg insufflation pressure (standard group)
Number of subjects: 80
Study 37348272 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization rate in patients with severely reduced LVEF
Number of subjects: 1657
Study 37348272 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality in patients with severely reduced LVEF
Number of subjects: 1657
Study 37348272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of optimal cardioprotective therapy at discharge
Number of subjects: 1657
Study 37348348 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year icotinib (125 mg thrice daily)
Number of subjects: 109
Study 37348348 — intervention group
Group type: COMPARATOR
Intervention: 1-year icotinib (125 mg thrice daily)
Number of subjects: 109
Study 37348519 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.1 monovalent booster (50 μg)
Number of subjects: 3548
Study 37348519 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.1 bivalent booster (50 μg)
Number of subjects: 3548
Study 37348519 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 (50 μg)
Number of subjects: 3548
Study 37348524 — intervention group
Group type: EXPERIMENTAL
Intervention: Aviptadil
Number of subjects: 473
Study 37348524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 37348524 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 473
Study 37348524 — intervention group
Group type: COMPARATOR
Intervention: Remdesivir matched placebo
Number of subjects: 473
Study 37348800 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing (LBBAP)
Number of subjects: 870
Study 37348800 — intervention group
Group type: EXPERIMENTAL
Intervention: His-Bundle Pacing (HBP)
Number of subjects: 870
Study 37348816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferumoxytol (2 infusions of 510 mg approximately 7 days apart)
Number of subjects: 124
Study 37348817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferumoxytol (2 infusions of 510 mg)
Number of subjects: 124
Study 37348817 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (325 mg twice daily)
Number of subjects: 124
Study 37348996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy
Number of subjects: 0
Study 37348996 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 37349083 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 37349083 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study 37349100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (4 mg/kg)
Number of subjects: 85
Study 37349132 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Device (AD)
Number of subjects: 0
Study 37349132 — intervention group
Group type: COMPARATOR
Intervention: Inactive Device (ID)
Number of subjects: 0
Study 37349632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 26
Study 37349632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tACS
Number of subjects: 26
Study 37349632 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26
Study 37349673 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid EtG test strips
Number of subjects: 505
Study 37349694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment
Number of subjects: 20
Study 37349703 — intervention group
Group type: EXPERIMENTAL
Intervention: IntuBrite® (INT)
Number of subjects: 86
Study 37349703 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MCL)
Number of subjects: 86
Study 37349747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist-administered cognitive behavioural therapy (D-CBT, n=36)
Number of subjects: 82
Study 37349747 — intervention group
Group type: COMPARATOR
Intervention: Four Habits Model combined with midazolam (Four Habits/midazolam, n=41)
Number of subjects: 82
Study 37349747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist-administered cognitive behavioural therapy (D-CBT)
Number of subjects: 82
Study 37349747 — intervention group
Group type: COMPARATOR
Intervention: Four Habits Model combined with midazolam (Four Habits/midazolam)
Number of subjects: 82
Study 37349825 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health education tool (dHET)
Number of subjects: 40
Study 37349825 — intervention group
Group type: COMPARATOR
Intervention: Standard consent (SC)
Number of subjects: 40
Study 37349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended self-management program 'Partner in Balance'
Number of subjects: 100
Study 37349828 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 100
Study 37349841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 25 mg
Number of subjects: 132
Study 37349841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg
Number of subjects: 132
Study 37349841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 132
Study 37349841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 37349841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 132
Study 37349895 — intervention group
Group type: EXPERIMENTAL
Intervention: FET
Number of subjects: 606
Study 37349895 — intervention group
Group type: COMPARATOR
Intervention: fresh-ET
Number of subjects: 606
Study 37349895 — intervention group
Group type: COMPARATOR
Intervention: NC
Number of subjects: 606
Study 37349895 — intervention group
Group type: EXPERIMENTAL
Intervention: FET (girls)
Number of subjects: 606
Study 37349895 — intervention group
Group type: EXPERIMENTAL
Intervention: FET (boys)
Number of subjects: 606
Study 37349895 — intervention group
Group type: COMPARATOR
Intervention: fresh-ET (girls)
Number of subjects: 606
Study 37349895 — intervention group
Group type: COMPARATOR
Intervention: NC (girls)
Number of subjects: 606
Study 37349895 — intervention group
Group type: COMPARATOR
Intervention: NC (boys)
Number of subjects: 606
Study 37350052 — intervention group
Group type: EXPERIMENTAL
Intervention: Viz RECRUIT SDH (AI-based software)
Number of subjects: 19
Study 37350052 — intervention group
Group type: COMPARATOR
Intervention: Pre-AI cohort
Number of subjects: 19
Study 37350052 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-AI cohort
Number of subjects: 19
Study 37350119 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0
Study 37350280 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model for stroke prediction based on history of previous stroke, insulin-treated diabetes, and plasma N-terminal pro-B-type natriuretic peptide level.
Number of subjects: 5126
Study 37350280 — intervention group
Group type: EXPERIMENTAL
Intervention: Third tertile risk score for stroke prediction.
Number of subjects: 5126
Study 37350280 — intervention group
Group type: EXPERIMENTAL
Intervention: Second tertile risk score for stroke prediction.
Number of subjects: 5126
Study 37350280 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the third tertile risk score.
Number of subjects: 5126
Study 37350280 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model discrimination.
Number of subjects: 5126
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD extraction procedure
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple manual traction for lead removal
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization time for non-infectious indications
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization time for infectious indications
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-extraction intravenous antibiotics
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy duration
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-implantation during the same procedure
Number of subjects: 71
Study 37350404 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications over a median follow-up period
Number of subjects: 71
Study 37350492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement at presentation, threshold of 2 ng/L
Number of subjects: 41103
Study 37350492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement at presentation, threshold of 5 ng/L
Number of subjects: 41103
Study 37350492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement at presentation, threshold of 99th centile
Number of subjects: 41103
Study 37350492 — intervention group
Group type: COMPARATOR
Intervention: External validation cohort
Number of subjects: 41103
Study 37350574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) plus best medical treatment (BMT)
Number of subjects: 824
Study 37350574 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 824
Study 37350585 — intervention group
Group type: EXPERIMENTAL
Intervention: iTind
Number of subjects: 50
Study 37350968 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with EC/EP for two cycles followed by concurrent palliative HFRT and two cycles of atezolizumab with EC/EP, then atezolizumab every 3 weeks for a maximum of 2 years.
Number of subjects: 40
Study 37350968 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent hypofractionated thoracic radiotherapy (HFRT) with immunochemotherapy.
Number of subjects: 40
Study 37350989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide (1.0 mg/kg/h)
Number of subjects: 219
Study 37350989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 37350990 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted intermediate dose of low-molecular-weight heparin
Number of subjects: 1000
Study 37350990 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose of low-molecular-weight heparin
Number of subjects: 1000
Study 37351068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume strategy
Number of subjects: 98
Study 37351068 — intervention group
Group type: COMPARATOR
Intervention: Intermediate tidal volume strategy
Number of subjects: 98
Study 37351105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention focusing on improving diet, physical activity, and mental health in the mother, and supporting breastfeeding, delaying solid food introduction, reducing sweetened beverage consumption, increasing family physical activity, and improving parental responsiveness.
Number of subjects: 0
Study 37351105 — intervention group
Group type: COMPARATOR
Intervention: Active guidelines-based usual-care group (Control)
Number of subjects: 0
Study 37351147 — intervention group
Group type: EXPERIMENTAL
Intervention: Y90 TARE using personalized dosimetry
Number of subjects: 18
Study 37351372 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy
Number of subjects: 105
Study 37351408 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTi-TE archwires
Number of subjects: 52
Study 37351408 — intervention group
Group type: COMPARATOR
Intervention: NiTi-PSE archwires
Number of subjects: 52